98 results about "Enhanced bioavailability" patented technology

A composition contains a BCS Class II or IV drug that is acid-base solubilized with a pharmaceutically acceptable acid, and which is complexed with β-cyclodextrin. The β-cyclodextrin complexed drug exhibits enhanced bioavailability. The drug may be formulated for oral administration and / or to exhibit rapid release when administered. Preferable compositions may contain no crosslinked or polymerized non-active components.

Solid lipid nanoparticles (SLNs) for delivery of bioactive compounds are disclosed. The SLNs comprise a lipid matrix and surfactant layer encapsulating at least one bioactive compound selected from vitamins, minerals, enzymes, algae-derived bioactives, proteins, peptides, amino acids, antioxidants, small synthetic molecules, plant-derived volatile compounds, or botanical extracts. The SLNs exhibit submicron particle size, low polydispersity, and sufficient surface charge to ensure colloidal stability and efficient delivery. In one embodiment, algae-based bioactives, such as phycocyanin or fucoxanthin, are encapsulated using only natural and sustainable lipids and surfactants to improve bioavailability and support environmentally friendly formulations. The SLNs may be formulated for oral, topical, transdermal, injectable, ophthalmic, mucosal, textile, veterinary, or agricultural administration. Applications include human and animal health, functional foods, skincare, nutrient supplementation, and crop treatment. The disclosed SLNs offer a biocompatible and scalable delivery system that protects sensitive compounds, enables sustained release, and enhances absorption across diverse industries.

Aspects of disclosure relate to a composition and methodology for treating menopause symptoms utilizing a cannabinoid-based nanoplatform composition. The composition includes phytocannabinoids like CBD, CBG, and CBN, alongside isoflavones and polyphenols, all integrated into nanoplatform designed for enhanced bioavailability and controlled release. The formulation is designed to alleviate key menopause-related issues, including vasomotor symptoms (VMS), genitourinary syndrome of menopause (GSM), bone loss, mood disturbances, and sleep disorders, while addressing cardiovascular disease (CVD) risks. The composition combines cannabinoids, such as CBD, with isoflavones and polyphenols, and is incorporated into nanoplatforms for enhanced delivery and efficacy. Additionally, the disclosure includes a kit comprising oral capsules, intravaginal ovules, and instructions for use. The capsules contain a blend of cannabinoids, flavonoids, and polyphenols, while the ovules are composed of CBD and cocoa butter. The kit provides a comprehensive solution for managing menopause symptoms and mitigating cardiovascular risks.

We are disclosing derivatives of 5-hydroxylated polymethoxyflavones. The derivatives offer enhanced oral bioavailability and improved intestinal permeability. The derivatives of the invention release the biologically active 5-hydroxylated polymethoxyflavones that are activated by chemical or enzymatic processes in the GI Tract. The derivatives are constructed as bioreversible prodrugs containing the bioactive molecules covalently linked with lipids like fatty acids, glycerides or phospholipids. The derivatives are useful against inflammatory conditions and aging. Formulations including the derivatives are also disclosed.

The invention discloses a multi-system function regeneration factor composition as well as a preparation method and application thereof. The multi-system function regeneration factor composition is prepared from the following components in parts by mass: 0.8 to 2.4 parts of melatonin, 84 to 126 parts of nicotinamide ribose and 42 to 84 parts of resveratrol. According to the multi-system functional regeneration factor composition disclosed by the invention, through scientific proportioning and synergistic effect of melatonin, nicotinamide ribose and resveratrol, the functions of stem cells are strongly activated, proliferation of the stem cells is remarkably promoted, the stemness maintaining capability of the stem cells is improved, osteogenesis and adipogenesis differentiation potential is enhanced, and the regeneration effect of the stem cells is improved. Meanwhile, an NAD < + > metabolic pathway is activated so as to strengthen cell energy and anti-aging capability. The capsule adopts the design of combining quick-release pellets and sustained-release pellets, the quick-release part can quickly release melatonin, the local drug concentration can be increased in a short time, and stem cell activation signals can be quickly started; and the sustained release part slowly releases nicotinamide ribose and resveratrol to maintain the long-acting stability of the drug concentration, so that the effect taking speed is ensured, the action time is prolonged, and the bioavailability is greatly improved.

The present application relates to a kind of bone repair compositions and its preparation method, belong to biological medicine technical field, pharmaceutical composition includes acid anhydride bovine beta-lactoglobulin peptide, casein phosphopeptide, yak bone peptide, loquat leaf extract, pterostilbene, honeysuckle chlorogenic acid and cyperus rotundus extract;Acid anhydride bovine beta-lactoglobulin peptide is prepared using special enzymolysis method.Acid anhydride bovine beta-lactoglobulin peptide, casein phosphopeptide and yak bone peptide are loaded using carboxymethyl chitosan-hydroxyapatite composite microspheres, then using sodium alginate-sodium carboxymethyl cellulose containing loquat leaf extract, pterostilbene, honeysuckle chlorogenic acid and cyperus rotundus extract one coating, then using sodium alginate-sodium carboxymethyl cellulose secondary coating.The present application develops high-efficiency pharmaceutical combination component, using polymer material to coat drug to form sustained-release system, improve bioavailability, using granular carrier to increase the stability and solubility of drug, promote intestinal absorption, improve bone repair process.

The present invention relates to a protein tyrosine kinase inhibitor and an ophthalmic preparation thereof. The protein tyrosine kinase inhibitor not only effectively antagonizes the activity of a VEGFR receptor tyrosine kinase, but also improves the pharmacokinetic properties thereof, while exhibiting high selectivity in inhibiting the activity of an "off-target" EGFR tyrosine kinase, thereby reducing or avoiding side effects, particularly those affecting the eyes. The preparation can greatly improve the solubility of the protein tyrosine kinase inhibitor compound, prolong the residence time of the compound on the ocular surface, increase exposure in fundus tissue, and improve the bioavailability.

The present application belongs to the technical field of oral solid preparation, and particularly relates to a mosapride citrate orally disintegrating tablet and a preparation method thereof. Raw and auxiliary materials comprise mosapride citrate, a filling agent, a disintegrating agent, a glidant, a lubricant and a flavoring agent. The present application screens and optimizes the auxiliary material formula, adopts dry granulation, optimizes the preparation process, improves the compressibility and fluidity of the material, saves energy, improves the production quality and stability, makes the prepared orally disintegrating tablet disintegrate rapidly, has excellent taste, greatly improves the medication compliance of patients, simultaneously improves the drug dissolution and improves the bioavailability. In addition, compared with other types of solid oral preparations of the product, the mosapride citrate orally disintegrating tablet is particularly suitable for the elderly and patients with difficulty in swallowing, and provides convenience in special and urgent situations such as lack of drinking water for taking medicine.

An antifungal solution, a preparation method and use thereof are provided, belonging to the technical field of medicine. The antifungal solution includes an antifungal drug and a solvent as raw materials; where the antifungal drug and the solvent are at a mass ratio of (0.1-1):(18-318); and the solvent includes an ionic liquid, an alcohol organic solvent, and water. The ionic liquid has excellent solubility, skin penetration-promoting performance, and antifungal effect; the water can destroy an original polar network of the ionic liquid, forming smaller soluble ion groups, which greatly increase a miscibility window; the alcohol organic solvent can form a cosolvent with the ionic liquid and the water, thereby helping miscibility. The antifungal solution can ensure that the drug in a system is maintained in a dissolved state, thereby improving bioavailability and ensuring better therapeutic effects while reducing dosage.

The invention relates to the technical field of medicine and functional food delivery, in particular to a high-stability lipidosome coating containing hydrogen molecules and active substances and a preparation method of the lipidosome coating. The core of the coating is lipidosome loaded with nano-bubble hydrogen-rich water and active substances, and the outer layer of the coating is formed by coating an edible high-barrier material. Generally, in the coating and the method, a physical barrier is constructed by utilizing the primary protection of the lipidosome on the active substance and the extremely high barrier property of the beewax or the hard candy film on the active substance, especially gas, so that the rapid dissipation of hydrogen molecules in the inner core lipidosome is effectively prevented, and the problem of stable storage of the hydrogen molecules in the wrapping substance is solved. The stability of the active ingredients is jointly improved. The liposome has targeting property, can realize intestinal targeted release and slow release effects of active substances and hydrogen molecules, and improves bioavailability. And finally, the product can be prepared into various forms such as microspheres, sugar capsules or wrappers and the like, and can be conveniently delivered and eaten as functional foods, health-care products or medicines and the like.

A composition for enhanced bioavailability of curcumin comprising a curcuminoid mixture and an essential oil of turmeric, wherein the curcuminoid mixture comprises a curcumin-keto compound, a curcumin-enol compound, a bisdemethoxycurcumin, a demethoxycurcumin, wherein a weight ratio of the curcumin-keto compound to the curcumin-enol compound ranges from about 0.12 - 0.20 : 0.8 - 0.88. A composition for enhanced lymphatic bioavailability of curcumin comprising a curcuminoid mixture and an essential oil of turmeric, wherein the curcuminoid mixture comprises a curcumin-keto compound, a curcumin-enol compound, a bisdemethoxycurcumin, a demethoxycurcumin, wherein a weight ratio of the curcumin-keto compound to the curcumin-enol compound ranges from about 0.12 - 0.20 : 0.8 - 0.88. Methods for making the composition for enhanced bioavailability of curcumin. Methods for making the composition for enhanced lymphatic bioavailability of curcumin.

The invention relates to an formulation for cardiac support supplements and the method of its preparation by using molecular-level mixing technology. The method involves preparing molecular-level emulsions of alpha-lipoic acid, acetyl L-carnitine, and coenzyme Q10, followed by spray drying to produce a homogeneous powder premix. This approach ensures precise dosage control, enhanced bioavailability, and improved stability, making it a valuable advancement in the field of nutraceutical and pharmaceutical formulations.

The embodiment of the invention provides a buccal product and a preparation method thereof, the buccal product provided by the embodiment of the invention comprises a functional layer, the functional layer comprises active substances, a slow-release base material and a film-forming base material, the active substances comprise nicotine and nicotine salt, and at least part of nicotine is embedded in the slow-release base material; wherein the nicotine and the nicotine salt are compounded into an active substance, the nicotine salt can realize quick release, and the sustained-release base material is used for embedding the nicotine, so that the nicotine can be inhibited from volatilizing in the drying process and is gradually dissociated in saliva, long-acting sustained release is realized, the bioavailability is improved, the release rate of the active substance can be controlled, and the sustained-release effect of the nicotine is improved. Therefore, the effects of early-stage quick release and later-stage slow release are achieved, the volatilization loss after drying can be reduced, and the validity period is prolonged; therefore, the buccal product provided by the embodiment of the invention can effectively solve the problem that the active substances in the existing buccal product are easy to release too fast in the initial stage or insufficient in the later stage.

The invention discloses a two-way positioning release sustained-release pharmaceutical composition and a preparation method thereof, the pharmaceutical composition is a double-layer tablet, and the double-layer tablet comprises an upper-layer tablet and a lower-layer tablet. The upper-layer tablet is a slow-release intragastric positioning release preparation part and contains 1 / 3 marked amount of active ingredients; the lower-layer tablet is a quick-release gastrointestinal tract release preparation part and contains 2 / 3 labeled amount of active ingredients. A new preparation technology and a new dosage form are adopted, the lower-layer tablet in the double-layer tablet can enable the medicine to be rapidly disintegrated in the stomach, the disintegrated medicine forms a particle dispersion, and the particle dispersion can be rapidly emptied by the stomach to enter the intestinal tract, so that the absorption of the medicine is promoted; the upper-layer tablet floats in the stomach after absorbing water, then the medicine is slowly dissolved out, the medicine dissolved out of the preparation can be metabolized into active metabolite OP-1118 in an acid environment in the stomach, then the active metabolite OP-1118 is absorbed through the gastrointestinal tract, and part of the medicine can be absorbed immediately after uniformly and slowly entering the intestinal tract, so that the bioavailability is improved.

The invention relates to the technical field of medicine, and provides a semeglutide oral patch for buccal mucosa administration and application of the semeglutide oral patch, the semeglutide oral patch comprises a tablet layer I and a tablet layer II, the tablet layer I comprises semeglutide or pharmaceutically acceptable salt thereof, a biological adhesive and an absorption enhancer; the sheet layer II comprises an anti-sticking material; the biological adhesive is carbomer which is subjected to neutralization and drying treatment. The stability of the oral patch can be remarkably improved, the oral patch can permanently and stably act on buccal mucosa, an excellent absorption promoting effect is achieved, meanwhile, invalid release of medicine is further reduced, and bioavailability is improved.

Methods for chemically modifying bioactive triterpene compounds to increase the bioavailability thereof. The resulting triterpene chemical compounds, having enhanced bioavailability, are useful in pharmaceutical compositions, alone, in combination with, or complexed with therapeutic drugs for the treatment of diseases such as cancers.

(Main claim): A food supplement comprising collagen hydrolysate and a combination of vitamin C, zinc, vitamin E, silicon dioxide and copper, characterized in that the components are in a composition that causes rapid and uniform dispersion in aqueous liquids and improved bioavailability of the collagen hydrolysate.

The invention provides a drug-drug co-amorphous substance co-carrying active traditional Chinese medicine components, namely breviscapine and cepharanthine. The prescription of the drug-drug co-amorphous substance does not contain any auxiliary materials, the preparation method is simple, convenient and efficient, special processes and equipment are not needed, the cost is low, and industrialization is easy. The prepared breviscapine-cepharanthine powder is in an amorphous state, the water solubility of indissolvable drugs breviscapine and cepharanthine can be improved at the same time, the in-vitro antioxidant activity is superior to that of raw drugs, further preparation forming is facilitated, and the bioavailability is improved.

The application discloses a medical dressing for wound repair and a preparation method thereof. The dressing comprises a gel matrix and modified growth factor-encapsulated PLGA microspheres. The modified growth factor-encapsulated PLGA microspheres are growth factor-encapsulated PLGA microspheres modified with alkali lignin on the surface. The modified growth factor-encapsulated PLGA microspheres can effectively prevent ultraviolet damage of growth factors and improve bioavailability. Meanwhile, the modified growth factor-encapsulated PLGA microspheres have a suitable degradation period, can release growth factors to promote cell proliferation and wound healing in the proliferation period of a wound, and are stably dispersed in an aqueous phase, so that the dispersion uniformity of the modified growth factor-encapsulated PLGA microspheres in the dressing is improved, and batch stability of the dressing is improved.

The invention discloses a medical dressing for wound repair and a preparation method thereof. The dressing comprises a gel matrix and modified PLGA (poly (lactic-co-glycolic acid)) microspheres for encapsulating growth factors, the modified PLGA microspheres for encapsulating the growth factors are PLGA microspheres for encapsulating the growth factors, and the surfaces of the PLGA microspheres are modified with alkali lignin. The modified PLGA microspheres encapsulating the growth factors can effectively prevent ultraviolet damage of the growth factors, and the bioavailability is improved; meanwhile, an appropriate degradation period is achieved, and growth factors can be slowly released in the proliferation period of the wound to promote cell proliferation and wound healing; furthermore, the PLGA microspheres with the alkali lignin surface modified and encapsulated with the growth factors are stably dispersed in a water phase, so that the dispersion uniformity of the PLGA microspheres in the dressing is improved, and the batch stability of the dressing is improved.

Aspects of the disclosure relate to a composition and methods for treating breast cancer using a cannabinoid-based nanoplatform. The composition comprises phytocannabinoids, including THC, CBD, CBG, and CBC, incorporated into nanoparticles for enhanced bioavailability and controlled release. The method involves administering the composition to patients with breast cancer, particularly stages I and II, to inhibit VEGF pathways and induce apoptosis. The treatment targets estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), HER2-positive, and triple-negative breast cancers. Aspects of the disclosure further provide the production of the composition using nano emulsification techniques to create nanoparticles smaller than 200 nm. This composition offers a novel, targeted approach to reducing tumor growth and metastasis in breast cancer patients.

The invention relates to the technical field of pharmaceutical preparations, and provides a blumea balsamifera oil nano-micelle as well as a preparation method and application thereof. The preparation method comprises the following steps: mixing blumea balsamifera oil, poloxamer 407 and trichloromethane to obtain a mixed solution; and evaporating trichloromethane in the mixed solution to dryness, mixing the remainder with water, and hydrating to obtain the blumea balsamifera oil nano-micelle. The nano preparation is combined with the blumea balsamifera oil which is a superior traditional Chinese medicine extract, so that the drug delivery can be effectively improved, the bioavailability can be improved, meanwhile, the cytotoxicity of the blumea balsamifera oil can be reduced, and the safety can be improved; in-vivo and in-vitro anti-inflammatory activity test results show that the low-concentration blumea balsamifera oil nano-micelle has the best inhibition effect on mouse ear swelling, and the inhibition rate can reach 60.1%; the blumea balsamifera oil nano-micelle has a remarkable inhibition effect on the release of an inflammatory mediator NO and cell factors TNF-alpha and IL-6 generated by RAW264.7 cells induced by LPS (lipopolysaccharide).

The present application relates to the technical field of microcapsule powder, and discloses 5-hydroxytryptophan microcapsule powder and a preparation method thereof.The microcapsule powder comprises 5-hydroxytryptophan and wall material, and the wall material comprises sodium octenyl succinate starch and maltodextrin.The preparation method mainly comprises the following steps: sodium octenyl succinate starch and maltodextrin are added into water, stirred uniformly and dissolved; 5-hydroxytryptophan is continuously added, sheared by a high-pressure homogenizer to form a coarse emulsion; the coarse emulsion is ground by a sander to obtain an emulsion; and the emulsion is subjected to a spray drying powder preparation process to obtain the microcapsule powder.The 5-hydroxytryptophan microcapsule powder prepared by the method has good water dispersibility, the water dispersion liquid is stable, the retention rate of 5-hydroxytryptophan is high, the microcapsule particle size is not greater than 0.5 microns, the bioavailability can be effectively improved, and the medicinal activity is improved.The preparation method is simple in operation, low in energy consumption, does not use organic solvents, and is suitable for industrial production.

The invention relates to a bile acid-containing feed for raw fish and a preparation method of the bile acid-containing feed, and belongs to the technical field of fish feeds and additives. The feed is prepared from the following raw materials in parts by mass, comprising 30 to 40 parts of fish meal, 20 to 30 parts of puffed soybean meal, 10 to 20 parts of puffed wheat flour, 5 to 12 parts of fish oil, 1 to 2 parts of monocalcium phosphate, 1 to 3 parts of a vitamin and mineral premix, 3 to 5 parts of a small trash fish fermentation product, 0.1 to 0.3 part of bile acid-chitosan oligosaccharide-phytase composite microspheres, 0.1 to 0.25 part of bile acid-beta-glucan-probiotic microcapsules, 0.1 to 0.2 part of tocopherol and 0.05 to 0.2 part of an antioxidant. According to the invention, the combination inactivation of bile acid and phytic acid can be reduced, the bioavailability is improved, and the synergistic effects of targeted slow release of intestinal tracts, enhancement of immune regulation and liver protection are realized by organically combining the metabolic regulation function of bile acid with the immune enhancement function of beta-glucan and the flora regulation function of probiotics.

Disclosed in the present application is a crystal polymorph of potassium N-[8-(2-hydroxybenzoyl)amino]octanoate, wherein the crystal polymorph of potassium N-[8-(2-hydroxybenzoyl)amino]octanoate is crystal Form I, and the crystal Form I has at least an X-ray powder diffraction pattern with characteristic peaks represented by 2θ° of 7.83±0.2, 26.64±0.2 and 18.89±0.2. The crystal polymorph of potassium N-[8-(2-hydroxybenzoyl)amino] octanoate provided by the present application has four crystal forms, has high solubility and strong stability, can deliver drugs more effectively, increases the permeability of the delivered drugs in the gastrointestinal tract, and is beneficial to the preparation of oral preparations, such that preventive and / or therapeutic drugs can be better delivered into the body to achieve the effect of improving the bioavailability.

The invention generally refers to pharmaceutical uses of tetracyclic terpene 3-ols, as an example lanosta-8,24-dien-3-ol, bearing polar and / or charged moieties, as anti-inflammatory, anti-cancer and analgesic agents via the inhibition of the disordered activation of serine-threonine protein kinases, particularly PKC.

The utility model belongs to the technical field of pharmaceutical machinery, and particularly relates to a baking oven suitable for wall breaking of cicada slough. The cicada slough is treated by adopting the baking box made of non-metal materials, so that the damage of the metal materials to the medicinal effect of the cicada slough can be effectively avoided. Meanwhile, a second heating pipe and a first heating pipe are arranged to conduct dehumidification and drying wall breaking treatment on the cicada slough, so that it is guaranteed that the head, eyes, legs, claws and other hard parts of the cicada slough can be effectively treated in the follow-up mashing and grinding process, and finally effective ingredients of the cicada slough are all prepared into cicada slough powder. The raw cicada slough is converted into cooked cicada slough after the cicada slough is dried and subjected to wall breaking treatment in a baking oven, the cicada slough powder obtained by further processing can be directly applied to medicated food, food, health care products and traditional Chinese medicine preparations, and the bioavailability can be effectively improved. According to the utility model, the PLC is adopted for automatic control, so that the manual intervention can be reduced, and the pollution risk can be reduced.

Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and / or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

The OAB-14 tablet comprises an OAB-14 suspension, a high-molecular polymer, a filling agent, a disintegrating agent and a lubricating agent, and the total weight of the OAB-14 tablet is the solid weight and does not contain water and an organic solvent according to the weight percentage. The solid weight of the OAB-14 suspension (the solid weight of the OAB-14 suspension excluding the weight of the water and the organic solvent) accounts for 30%-67%, the high-molecular polymer accounts for 4%-35%, the filler accounts for 7%-48.5%, the disintegrating agent accounts for 1%-16%, the lubricant accounts for 0.5%-2%, the OAB-14 accounts for 19%-47%, and the ratio of the OAB-14 to the high-molecular polymer is (4: 1)-(4: 3); the OAB-14 suspension comprises OAB-14, a stabilizer and an aqueous solution, and the mass ratio of the OAB-14 to the stabilizer to the aqueous solution is 1: (0.08-16): (1.5-28); the particle size d (0.5) of the OAB-14 is 1 to 1000 nm, and the particle size d (0.9) of the OAB-14 is 2 to 3000 nm. The solubility and fat solubility of the OAB-14 are increased, the purposes of improving bioavailability and penetrating a blood-brain barrier are achieved, and the key problem of OAB-14 patent medicine is solved. The invention further keeps the treatment effect equivalent to that of OAB-14 suspension, is convenient to store and carry, and improves the compliance of patients.

A composition contains a BCS Class II or IV drug that is acid-base solubilized with a pharmaceutically acceptable acid, and which is complexed with β-cyclodextrin. The β-cyclodextrin complexed drug exhibits enhanced bioavailability. The drug may be formulated for oral administration and / or to exhibit rapid release when administered. Preferable compositions may contain no crosslinked or polymerized non-active components.